Note: This article is written for informational publishing purposes and should not be treated as legal, medical, or regulatory advice.
The Food and Drug Administration has suddenly become the federal agency equivalent of a very busy air-traffic controller. On one runway: the Make America Healthy Again initiative, better known as MAHA, which is pressing federal health agencies to confront chronic disease, food additives, synthetic dyes, nutrition transparency, and the long-debated GRAS pathway. On another runway: the Modernization of Cosmetics Regulation Act of 2022, or MoCRA, which gives FDA its most meaningful expansion of cosmetics authority in decades.
Together, these two forces are reshaping FDA priorities across food, dietary supplements, personal care products, cosmetics, labeling, adverse event reporting, ingredient safety, and manufacturing oversight. That is a lot of alphabet soup, even by Washington standards. But behind the acronyms is a practical question for companies and consumers alike: what does FDA’s growing to-do list actually mean?
The short answer is that the agency is being asked to move from a more reactive model toward a more transparent, prevention-focused, data-driven model. The longer answer is more interesting. It involves synthetic food dyes, “Generally Recognized as Safe” ingredients, fragrance allergens, talc testing, PFAS in cosmetics, mandatory cosmetic facility registration, product listings, serious adverse event reporting, and a wave of rulemaking that could change how brands formulate, label, document, and defend their products.
What MAHA Adds to FDA’s Agenda
The Make America Healthy Again initiative places chronic disease prevention at the center of federal health policy. Its stated focus includes childhood chronic disease, nutrition, environmental exposures, lifestyle, food quality, drug quality, transparency in research, and concerns about conflicts of interest. For FDA, that translates into pressure to scrutinize ingredients, labeling systems, and safety pathways that have long been familiar to industry but nearly invisible to the average shopper.
One of the clearest MAHA-related FDA moves is the push to phase out petroleum-based synthetic food dyes. HHS and FDA announced measures aimed at removing several certified color additives from the food supply, including FD&C Red No. 40, Yellow No. 5, Yellow No. 6, Blue No. 1, Blue No. 2, and Green No. 3. The agency has also discussed action involving Orange B and Citrus Red No. 2, while encouraging companies to transition toward natural color alternatives.
For consumers, the issue is easy to understand: nobody buys cereal because it is nutritionally improved by electric-blue marshmallow dust. For manufacturers, however, reformulation is not as simple as swapping one crayon for another. Natural colors can behave differently under heat, light, acidity, moisture, and shelf-life conditions. A strawberry-red beverage that looks cheerful in January can look like a sad science project by July if the formulation is not carefully rebuilt.
The GRAS Pathway Is Under the Microscope
Another MAHA-driven initiative involves the GRAS system, short for “Generally Recognized as Safe.” Under the current framework, companies may determine that certain substances are GRAS for their intended uses, sometimes without submitting a formal notice to FDA. Critics have long called this a loophole. Industry groups tend to describe it as a science-based pathway that supports innovation. Both sides agree on one thing: changing it would be a big deal.
FDA’s current regulatory agenda includes a proposed rule that would require mandatory submission of GRAS notices for human and animal food substances that are claimed to be GRAS, with exemptions for certain substances already listed, affirmed by regulation, or covered by FDA “no questions” letters. If finalized, this would mark a major shift away from private self-affirmation and toward a more public, FDA-visible system.
The practical impact could be enormous. Food, beverage, packaging, supplement, and ingredient companies may need to inventory substances, review safety files, update scientific support, and prepare for more scrutiny. For smaller companies, this may feel like being asked to clean the garage while someone from Washington holds a clipboard. For larger companies, it is a compliance, legal, scientific, and supply-chain project rolled into one.
MoCRA: The Cosmetics Law That Changed the Room
While MAHA is pushing FDA toward broader health and ingredient reform, MoCRA is transforming cosmetics oversight. Before MoCRA, FDA’s authority over cosmetics was relatively limited compared with its authority over drugs, devices, and food. The cosmetics marketplace, meanwhile, had grown into a massive ecosystem of moisturizers, sunscreens, serums, hair products, makeup, fragrances, nail products, tattoo inks, and hybrid products that sometimes seem to need their own passport.
MoCRA changed the baseline. It gave FDA new tools, including facility registration, product listing, mandatory serious adverse event reporting, records access, mandatory recall authority, safety substantiation requirements, fragrance allergen rulemaking, cosmetic good manufacturing practice rulemaking, and standardized testing requirements for asbestos in talc-containing cosmetics.
FDA has reported that MoCRA implementation has already produced a much clearer picture of the cosmetics marketplace. The agency now has data from more than 15,000 unique active cosmetic product facility registrations and more than 1 million unique active cosmetic product listings. Before MoCRA, participation in cosmetic registration programs was largely voluntary, which meant FDA was trying to monitor a huge market with a flashlight and a polite request.
Facility Registration and Product Listing: The New Baseline
Under MoCRA, cosmetic manufacturers and processors must register facilities with FDA and renew those registrations every two years. Responsible persons must list marketed cosmetic products, including ingredients, and update product information annually. This matters because FDA cannot oversee what it cannot see.
Product listing data gives the agency a better map of what is being sold in the United States. Facility registration helps FDA identify where cosmetic products are manufactured or processed. Together, these tools improve traceability, recall readiness, safety monitoring, and market intelligence.
For beauty brands, this creates a new operational reality. Compliance is no longer something that can live in a dusty binder labeled “later.” It must be built into product development, supplier qualification, formulation review, labeling, adverse event handling, and post-market surveillance. A brand selling facial oil from a spare bedroom and a multinational selling 400 shades of foundation may not have identical obligations, but both need to understand whether MoCRA applies to them.
Adverse Event Reporting Gets Serious
MoCRA also requires responsible persons to report serious adverse events associated with cosmetic products and maintain related records. This is a major change from the old system, where much cosmetic adverse event reporting was voluntary.
FDA has said that adverse event reports from industry increased significantly after MoCRA implementation. That does not necessarily mean products suddenly became more dangerous. It means the reporting system became more structured and more mandatory. In plain English: when the mailbox becomes official, more mail arrives.
This data can help FDA detect emerging safety signals, identify product categories that need closer attention, and improve public transparency. It also means companies need better internal systems for complaint intake, medical review, documentation, escalation, and timely reporting. The customer service inbox is no longer just about missing promo codes and broken pumps. Sometimes, it is the front door to a regulatory obligation.
Fragrance Allergens: Label Transparency Is Coming
Fragrance has always been one of the more mysterious corners of cosmetics labeling. A single word, “fragrance,” can represent a complex mixture of ingredients. For consumers with allergies or sensitivities, that can be frustrating. For brands, fragrance formulas can involve proprietary supplier information and trade-secret concerns.
MoCRA directs FDA to establish regulations requiring disclosure of certain fragrance allergens on cosmetic labels. FDA’s Unified Agenda has pointed to rulemaking on fragrance allergen disclosure, although timelines can shift. Once finalized, this rule could require label updates across perfumes, lotions, shampoos, conditioners, cleansers, deodorants, makeup, and other fragranced products.
Companies should not wait until the last minute. Smart preparation includes mapping fragrance components, talking with suppliers, monitoring international allergen disclosure rules, reviewing label space, and planning reformulation where necessary. Label redesign is never as quick as it looks. Somewhere, a packaging designer is already whispering, “Please, not another mandatory disclosure.”
Cosmetic GMPs: The Rule May Be Delayed, But the Expectation Is Not
MoCRA requires FDA to establish good manufacturing practice regulations for cosmetic facilities. The GMP rule has faced delays and has appeared as a longer-term regulatory action. Still, companies should not mistake delay for disappearance.
GMP expectations are likely to focus on manufacturing controls, sanitation, documentation, quality systems, personnel training, equipment, complaint handling, supplier controls, batch records, and contamination prevention. Many responsible manufacturers already follow voluntary cosmetic GMP standards, but MoCRA may eventually make baseline expectations more uniform across the market.
For consumers, GMPs are the boring-but-beautiful part of product safety. Nobody posts a viral TikTok about clean batch records, but those records matter when a contaminated product needs to be traced, investigated, and corrected. In cosmetics, glamour may sell the product, but quality systems keep the glamour from turning into a recall notice.
Talc, Asbestos, and the Challenge of Scientific Rulemaking
Talc-containing cosmetics remain a high-profile issue because talc can be contaminated with asbestos, a known human carcinogen, depending on mining and processing conditions. FDA issued a proposed rule in December 2024 to establish standardized testing methods for detecting and identifying asbestos in talc-containing cosmetic products. The proposal discussed methods such as Polarized Light Microscopy and Transmission Electron Microscopy with related analytical techniques.
In November 2025, FDA withdrew that proposed rule after receiving comments raising technical, legal, and practical issues. Importantly, the withdrawal did not erase FDA’s statutory obligation under MoCRA to establish standardized testing methods. It signaled that FDA intends to reconsider the best way to address asbestos testing while aligning with broader MAHA priorities and administrative law requirements.
This is a classic regulatory dilemma: move too slowly, and advocates accuse the agency of leaving consumers exposed; move too quickly, and the rule may face technical objections, litigation risk, or implementation problems. The result is a rulemaking process that is less like a sprint and more like assembling a microscope while riding a bicycle.
PFAS in Cosmetics: Small Percentage, Big Attention
MoCRA required FDA to assess the use of PFAS in cosmetic products and evaluate scientific evidence related to safety and risks. FDA published a report on PFAS in cosmetics, using product listing data made available through MoCRA implementation. The agency found that PFAS-containing cosmetic products represented a small share of listed products, but the issue remains significant because PFAS are persistent chemicals that attract intense public, state, federal, and litigation attention.
For brands, PFAS review is not only about intentional ingredients. It can also involve raw materials, packaging, processing aids, contamination risks, supplier documentation, and marketing claims. “PFAS-free” may sound simple on a label, but substantiating that claim can require careful testing, supplier controls, and legal review.
Why FDA’s New Workload Matters to Industry
FDA’s MAHA- and MoCRA-driven initiatives matter because they are not isolated policy decorations. They affect real business decisions: formulation, labeling, product development timelines, supplier contracts, quality systems, scientific substantiation, recall planning, and consumer communication.
A food company may need to reformulate products that rely on synthetic dyes. A supplement company may need to reassess whether certain ingredients depend on private GRAS conclusions. A cosmetics brand may need to register facilities, list products, document safety substantiation, strengthen complaint procedures, prepare for fragrance allergen disclosure, and monitor GMP rulemaking.
The companies best positioned for this new era will be the ones that treat compliance as a product-development function, not a last-minute legal spell cast over finished goods. In the new environment, the compliance team needs a seat near R&D, procurement, quality assurance, marketing, and executive leadership. Preferably with coffee.
What Consumers Should Expect
Consumers may notice gradual changes rather than one dramatic overnight shift. Food colors may change. Labels may become more detailed. Cosmetic brands may ask more questions about adverse events. Some products may be reformulated. Certain claims may become more carefully worded. Ingredient transparency may improve, especially where FDA rules require more disclosure.
That does not mean every product on the shelf is unsafe today or perfect tomorrow. Regulation is a process, not a magic wand. But MAHA and MoCRA both reflect a broader demand for more transparency about what Americans eat, apply to their skin, inhale from powders, or use around children.
Experience-Based Perspective: What This Feels Like on the Ground
For companies operating in food, cosmetics, or personal care, this moment feels like a compliance calendar that suddenly learned how to multiply. One department may be tracking food dye commitments, another is reviewing GRAS documentation, another is checking cosmetic product listings, and another is asking whether the fragrance supplier can provide allergen-level details without sending back a spreadsheet that looks like it was assembled during a thunderstorm.
In practice, the biggest challenge is not usually understanding that a rule exists. The challenge is translating regulatory change into daily workflow. A small cosmetics brand may know it must list products with FDA, but it still has to gather formulation data, identify the responsible person, coordinate with contract manufacturers, check exemptions, update records, and make sure future product launches do not forget the new process. A food company may know synthetic dye reformulation is coming, but it still has to test color stability, consumer acceptance, ingredient sourcing, cost changes, packaging images, and retailer deadlines.
The best experience-based lesson is simple: do not treat FDA initiatives as paperwork after the product is finished. Treat them as design requirements from day one. If a product development team creates a new candy, beverage, shampoo, face serum, or pressed powder without asking regulatory questions early, the company may discover late in the process that the formula is beautiful, marketable, and operationally inconvenient. That is the corporate version of baking a cake and then realizing the oven is in another state.
Another practical lesson is that supplier relationships matter more than ever. Brands increasingly need documentation: ingredient specifications, certificates of analysis, contaminant testing, allergen information, PFAS-related statements, safety data, manufacturing controls, and change notifications. A supplier that cannot answer reasonable compliance questions may become a business risk, even if its ingredient performs beautifully in the lab.
Documentation is also becoming a competitive advantage. Companies that can quickly show safety substantiation, complaint records, supplier controls, batch traceability, and labeling rationale will move faster when retailers, investors, regulators, or consumers ask questions. Companies that rely on “we think it’s fine” may find that sentence has a very short shelf life.
For marketers, the experience is also changing. Health and safety claims must be carefully supported. Terms like “clean,” “natural,” “non-toxic,” “free from,” and “no artificial colors” may attract consumer attention, but they also invite scrutiny. In the MAHA and MoCRA environment, vague wellness language is less useful than accurate, supportable, specific communication. Consumers want clarity, not a scented fog machine.
Finally, leadership teams should understand that FDA’s current direction is not just about avoiding penalties. It is about trust. Consumers are asking harder questions about ingredients. Retailers are tightening standards. States are passing their own laws. Plaintiffs’ lawyers are watching labels. Advocacy groups are monitoring chemicals. FDA is collecting more data. In that environment, strong compliance is not a bureaucratic burden; it is brand protection.
Conclusion
FDA’s MAHA- and MoCRA-driven initiatives show a clear shift toward greater transparency, stronger oversight, and more prevention-focused regulation. MAHA is pushing food and ingredient policy into the spotlight, especially around synthetic dyes, GRAS reform, and childhood health concerns. MoCRA is pulling cosmetics into a more modern regulatory structure, with facility registration, product listing, serious adverse event reporting, safety substantiation, fragrance allergen disclosure, GMP development, PFAS review, and talc/asbestos rulemaking.
For consumers, this could mean more information and potentially safer products. For companies, it means more homework, more documentation, and fewer places to hide behind outdated assumptions. The FDA’s list of initiatives may look complicated, but the big message is refreshingly plain: know what is in the product, prove it is safe for its intended use, label it honestly, monitor it after sale, and be ready to answer questions.
That may not fit on a bumper sticker, but it is probably the future of food and cosmetics regulation in America.
